Preclinical work has identified that combined TNF and immune checkpoint blockade is sufficient to overcome the immunosuppressive tumor microenvironment in two high risk pediatric brain tumors – TP53-mutant SHH medulloblastoma and DIPG. This evidence concerns the gene TNF and brain neoplasm.